[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. https://doi.org/10.1002/ijc.29210.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. https://doi.org/10.3322/caac.21262.
[3] Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019 Jan 17;5(1):5. https://doi.org/10.1038/s41572-018-0055-y.
[4] Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010 Jul 10;28(20):3271-7. https://doi.org/10.1200/JCO.2009.25.9820.
[5] Harbeck N, Gnant M. Breast cancer. Lancet. 2017 Mar 18;389(10074):1134-1150. https://doi.org/10.1016/S0140-6736(16)31891-8.
[6] Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015 Jul;26(7):1291-9. https://doi.org/10.1093/annonc/mdv022.
[7] Bates JP, Derakhshandeh R, Jones L, et al. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018 May 11;18(1):556. https://doi.org/10.1186/s12885-018-4441-3.
[8] Terry MB, Michels KB, Brody JG, et al. Breast Cancer and the Environment Research Program (BCERP). Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research. Breast Cancer Res. 2019 Aug 20;21(1):96. https://doi.org/10.1186/s13058-019-1168-2.
[9] Vaz-Luis I, Partridge AH. Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol. 2018 Apr;15(4):249-261. https://doi.org/10.1038/nrclinonc.2017.207.
[10] Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother. 2010 May;11(7):1089-100. https://doi.org/10.1517/14656561003702412.
[11] Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007 Dec 15;110(12):2640-7. https://doi.org/10.1002/cncr.23088.
[12] Ma S, Henson ES, Chen Y, et al. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016 Jul 21;7(7):e2307. https://doi.org/10.1038/cddis.2016.208.
[13] Weiland A, Wang Y, Wu W, et al. Ferroptosis and Its Role in Diverse Brain Diseases. Mol Neurobiol. 2019 Jul;56(7):4880-4893. https://doi.org/10.1007/s12035-018-1403-3.
[14] Nagpal A, Redvers RP, Ling X, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Res. 2019 Aug 13;21(1):94. https://doi.org/10.1186/s13058-019-1177-1.
[15] Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017 Oct 5;171(2):273-285. https://doi.org/10.1016/j.cell.2017.09.021.
[16] Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019 Nov;575(7784):688-692. https://doi.org/10.1038/s41586-019-1705-2.
[17] Yu M, Gai C, Li Z, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019 Oct;110(10):3173-3182. https://doi.org/10.1111/cas.14181.
[18] Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019 Jun 10;35(6):830-849. https://doi.org/10.1016/j.ccell.2019.04.002.
[19] Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019 Nov;575(7784):693-698. https://doi.org/10.1038/s41586-019-1707-0.
[20] Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015 Jan 15;160(1-2):48-61. https://doi.org/10.1016/j.cell.2014.12.033.
[21] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012 May 25;149(5):1060-72. https://doi.org/10.1016/j.cell.2012.03.042.
[22] Zille M, Kumar A, Kundu N, et al. Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors. eNeuro. 2019 Feb 15;6(1):ENEURO.0263-18.2019. https://doi.org/10.1523/ENEURO.0263-18.2019.
[23] Zhang J, Yang J, Zuo T, et al. Heparanase-driven sequential released nanoparticles for ferroptosis and tumor microenvironment modulations synergism in breast cancer therapy. Biomaterials. 2021 Jan;266:120429. https://doi.org/10.1016/j.biomaterials.2020.120429.
[24] Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010 Aug 4;2(43):43ra56. https://doi.org/10.1126/scisignal.3001127.
[25] Boult J, Roberts K, Brookes MJ, et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res. 2008 Jan 15;14(2):379-87. https://doi.org/10.1158/1078-0432.CCR-07-1054.
[26] Ferroptosis Is Inhibited in Lymph, Promoting Metastasis of Melanoma. Cancer Discov. 2020 Nov;10(11):1621. https://doi.org/10.1158/2159-8290.CD-RW2020-128.
[27] Chen X, Yu C, Kang R, et al. Iron Metabolism in Ferroptosis. Front Cell Dev Biol. 2020 Oct 7;8:590226. https://doi.org/10.3389/fcell.2020.590226.
[28] Brown RAM, Richardson KL, Kabir TD, et al. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Front Oncol. 2020 Apr 9;10:476. https://doi.org/10.3389/fonc.2020.00476.
[29] Akatsuka S, Yamashita Y, Ohara H, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One. 2012;7(8):e43403. https://doi.org/10.1371/journal.pone.0043403.
[30] Kaomongkolgit R, Cheepsunthorn P, Pavasant P, et al. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol. 2008 Jun;44(6):587-94. https://doi.org/10.1016/j.oraloncology.2007.08.005.
[31] Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013 May;13(5):342-55. https://doi.org/10.1038/nrc3495.
[32] Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther. 2020 Jun 30;5(1):108. https://doi.org/10.1038/s41392-020-00216-5.
[33] Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 2013 Mar;15(3):281-95. https://doi.org/10.1593/neo.122010.
[34] Adedoyin O, Boddu R, Traylor A, et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am J Physiol Renal Physiol. 2018 May 1;314(5):F702-F714. https://doi.org/10.1152/ajprenal.00044.2017.
[35] Noh SJ, Bae JS, Jamiyandorj U, et al. Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients. BMC Cancer. 2013 Nov 1;13:516. https://doi.org/10.1186/1471-2407-13-516.
[36] Li Q, Liu Q, Cheng W, et al. Heme Oxygenase-1 Inhibits Tumor Metastasis Mediated by Notch1 Pathway in Murine Mammary Carcinoma. Oncol Res. 2019 Jun 21;27(6):643-651. https://doi.org/10.3727/096504018X15415906335771.
[37] Yu H, Yang C, Jian L, et al. Sulfasalazine‑induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncol Rep. 2019 Aug;42(2):826-838. https://doi.org/10.3892/or.2019.7189.
[38] Almeida M, Soares M, Ramalhinho AC, et al. Prognosis of hormone-dependent breast cancer seems to be influenced by KEAP1, NRF2 and GSTM1 genetic polymorphisms. Mol Biol Rep. 2019 Jun;46(3):3213-3224. https://doi.org/10.1007/s11033-019-04778-8.
[39] Hartikainen JM, Tengström M, Winqvist R, et al. KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes. Clin Cancer Res. 2015 Apr 1;21(7):1591-601. https://doi.org/10.1158/1078-0432.CCR-14-1887.
[40] Kim MS, Lee WS, Jin W. TrkB Promotes Breast Cancer Metastasis via Suppression of Runx3 and Keap1 Expression. Mol Cells. 2016 Mar;39(3):258-65. https://doi.org/10.14348/molcells.2016.2310.
[41] Zhou XL, Zhu CY, Wu ZG, et al. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis. Oncogene. 2019 May;38(21):4028-4046. https://doi.org/10.1038/s41388-019-0698-5.
[42] Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019 Jul;19(7):405-414. https://doi.org/10.1038/s41568-019-0149-1.
[43] Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020 Aug 10;13(1):110. https://doi.org/10.1186/s13045-020-00946-7.
[44] Tang B, Zhu J, Li J, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signal. 2020 Oct 28;18(1):174. https://doi.org/10.1186/s12964-020-00663-1.
[45] Zhou B, Liu J, Kang R, et al. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020 Nov;66:89-100. https://doi.org/10.1016/j.semcancer.2019.03.002.
[46] Matsushita M, Freigang S, Schneider C, et al. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med. 2015 Apr 6;212(4):555-68. https://doi.org/10.1084/jem.20140857.
[47] Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019 May;569(7755):270-274. https://doi.org/10.1038/s41586-019-1170-y.
[48] Stockwell BR, Jiang X. A Physiological Function for Ferroptosis in Tumor Suppression by the Immune System. Cell Metab. 2019 Jul 2;30(1):14-15. https://doi.org/10.1016/j.cmet.2019.06.012.
[49] Lauko A, Thapa B, Venur VA, et al. Management of Brain Metastases in the New Era of Checkpoint Inhibition. Curr Neurol Neurosci Rep. 2018 Aug 18;18(10):70. https://doi.org/10.1007/s11910-018-0877-8.
[50] Solinas C, Gombos A, Latifyan S, et al. Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017 Nov 14;2(5):e000255. https://doi.org/10.1136/esmoopen-2017-000255.